Brady Stein is a Hematology physician affiliated with Northwestern University. OpenAlex indexes 260 publications with 4,163 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
645 N Michigan Ave Ste 1020
Chicago, IL 606112814
Telephone
312-695-6832Registry record last updated 16 Jan 2018.
Clinical trials
- Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Sponsor: Northwestern University
- Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Sponsor: Northwestern University
- Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.1%PD-1 inhibitor16.8%Pembrolizumab100%Part B, office-administered≥12 patientsMicrotubule Inhibitor16.1%Paclitaxel100%Part B, office-administered≥13 patients+ 5 more classes in this area
Blood & clotting
35.2%Parenteral Iron Replacement19.9%Iron sucrose100%Part B, office-administered≥17 patientsErythropoiesis-stimulating Agent13.5%Darbepoetin alfa100%Part B, office-administered≥12 patients+ 2 more classes in this area
Metabolism & gastrointestinal
26.1%Other antiemetics24.2%Fosaprepitant100%Part B, office-administered≥23 patientsSerotonin-3 Receptor Antagonist2%Palonosetron hcl100%Part B, office-administered≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”